Abstract
GW506U78 or nelarabine (Glaxo-SmithKline) is a nucleoside analog that is rapidly converted by cells of lymphoid lineage to its corresponding arabinosylguanine nucleotide triphosphate (araGTP). The triphosphate form of araG acts as a substrate for DNA polymerases and araG gets incorporated into the DNA, resulting in inhibition of DNA synthesis and subsequent cytotoxicity. It has been shown that nelarabine has activity as a single agent in patients with Tcell malignancies that have relapsed or are refractory to other therapy. The ongoing research on nelarabine has earned fast-track status from the U.S. Food and Drug Administration (FDA) for treatment of patients with T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma who have not responded to or whose disease has progressed during treatment with at least two standard regimens. It is likely that nelarabine will be a useful drug in the treatment of leukemic diseases in the future and therefore nelarabine is an interesting drug to study further. Here we present an overview of what is known about the mechanism of action of nelarabine and its status in clinical trials.
Keywords: Nelarabine, 9-β-D-arabinofuranosylguanine, acute T-cell leukemia, lymphoblastic lymphoma, nucleoside analogs
Reviews on Recent Clinical Trials
Title: Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies
Volume: 1 Issue: 3
Author(s): Sophie Curbo and Anna Karlsson
Affiliation:
Keywords: Nelarabine, 9-β-D-arabinofuranosylguanine, acute T-cell leukemia, lymphoblastic lymphoma, nucleoside analogs
Abstract: GW506U78 or nelarabine (Glaxo-SmithKline) is a nucleoside analog that is rapidly converted by cells of lymphoid lineage to its corresponding arabinosylguanine nucleotide triphosphate (araGTP). The triphosphate form of araG acts as a substrate for DNA polymerases and araG gets incorporated into the DNA, resulting in inhibition of DNA synthesis and subsequent cytotoxicity. It has been shown that nelarabine has activity as a single agent in patients with Tcell malignancies that have relapsed or are refractory to other therapy. The ongoing research on nelarabine has earned fast-track status from the U.S. Food and Drug Administration (FDA) for treatment of patients with T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma who have not responded to or whose disease has progressed during treatment with at least two standard regimens. It is likely that nelarabine will be a useful drug in the treatment of leukemic diseases in the future and therefore nelarabine is an interesting drug to study further. Here we present an overview of what is known about the mechanism of action of nelarabine and its status in clinical trials.
Export Options
About this article
Cite this article as:
Curbo Sophie and Karlsson Anna, Nelarabine- A New Purine Analog in the Treatment of Hematologic Malignancies, Reviews on Recent Clinical Trials 2006; 1 (3) . https://dx.doi.org/10.2174/157488706778250104
DOI https://dx.doi.org/10.2174/157488706778250104 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biosafety Considerations Using Gamma-Retroviral Vectors in Gene Therapy
Current Gene Therapy Quantum Dots in the Therapy: Current Trends and Perspectives
Mini-Reviews in Medicinal Chemistry Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews The Molecular Targets of Antitumor 2-deoxycytidine Analogues
Current Drug Targets The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Thyroid Hormone Treatment for Differentiated Thyroid Carcinoma: What Drug, How Long, What Dose?
Current Cancer Therapy Reviews Combining Gene Therapy and Radiation Against Cancer
Current Gene Therapy Using Biologic Agents in Pediatric Rheumatologic Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy p53-Induced Apoptosis and Inhibitors of p53
Current Medicinal Chemistry Retinoids as Therapeutic Agents: Today and Tomorrow
Mini-Reviews in Medicinal Chemistry Acute Hypersensitivity Reactions to Chemotherapy Agents: An Overview
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Stem Cells-Clinical Implications for Cancer Therapy
Current Stem Cell Research & Therapy Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?
Current Respiratory Medicine Reviews Fragmentation Study of Daphniphyllum Alkaloids by Electrospray Ionization Quadrupole Time-of-flight Mass Spectrometry
Current Pharmaceutical Analysis Telomerase Inhibitors as Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Angiogenesis in Chronic Lymphocytic Leukemia
Current Angiogenesis (Discontinued) Vanilloid Receptor Antagonists: Emerging Class of Novel Anti-Inflammatory Agents for Pain Management
Current Pharmaceutical Design